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Enteral nutrition in patients with acute renal failure.
Background. Systematic studies on safety and efficacy of en-
teral nutrition in patients with acute renal failure (ARF) are
lacking.
Methods. We studied enteral nutrition–related complications
and adequacy of nutrient administration during 2525 days of
artificial nutrition in 247 consecutive patients fed exclusively by
the enteral route: 65 had normal renal function, 68 had ARF
not requiring renal replacement therapy, and 114 required renal
replacement therapy.
Results. No difference was found in gastrointestinal or me-
chanical complications between ARF patients and patients with
normal renal function, except for high gastric residual volumes,
which occurred in 3.1% of patients with normal renal function,
7.3% of patients with ARF not requiring renal replacement
therapy, 13.2% of patients with ARF on renal replacement ther-
apy (P = 0.02 for trend), and for nasogastric tube obstruction:
0.0%, 5.9%, 14%, respectively (P < 0.001). Gastrointestinal
complications were the most frequent cause of suboptimal de-
livery; the ratio of administered to prescribed daily volume was
well above 90% in all the three groups. Definitive withdrawal
of enteral nutrition due to complications was documented in
6.1%, 13.2%. and 14.9% of patients, respectively (P = 0.09 for
trend). At regimen, mean delivered nonprotein calories were
19.8 kcal/kg (SD 4.6), 22.6 kcal/kg (8.4), 23.4 kcal/kg (6.5); pro-
tein intake was 0.92 g/kg (0.21), 0.87 g/kg (0.25), and 0.92 g/kg
(0.21), the latter value being below that currently recommended
for ARF patients on renal replacement therapy. Median fluid
intake with enteral nutrition was 1440 mL (range 720 to 1960),
1200 (720 to 2400), and 960 (360 to 1920).
Conclusion. Enteral nutrition is a safe and effective nutri-
tional technique to deliver artificial nutrition in ARF patients.
Parenteral aminoacid supplementation may be required, espe-
cially in patients with ARF needing renal replacement therapy.
Malnutrition, a common condition affecting patients
with acute renal failure (ARF), causes an increased risk
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of complications and death [1]. Nutritional support is thus
considered a cornerstone of ARF treatment [2].
The major body of evidence supports use of the enteral
instead of the parenteral route for nutrient administra-
tion in the critically ill [3, 4]. Although the same might
be appropriate for patients with ARF [2], so far no sys-
tematic studies on enteral nutrition have been conducted
in this category of patients [5]. In fact, published stud-
ies have dealt with patients with chronic renal failure on
hemodialysis [6, 7] or pediatric patients [8, 9].
Enteral nutrition offers some potential advantages
over parenteral nutrition in ARF. First, by using the more
concentrated formulas, it allows restraint of fluid adminis-
tration; second, it is less expensive than parenteral nutri-
tion; and third, it may have a positive impact on survival
[10]. On the other hand, theoretically at least, enteral
nutrition may be implemented with difficulties, due to the
gastrointestinal motility disorders of the uremic patients
[11], a problem which may become especially promi-
nent with the use of more concentrated enteral formulas.
Moreover, with use of the enteral diet formulas currently
available on the market, it may be difficult to achieve the
protein intake usually recommended in catabolic condi-
tions, such as ARF.
With the present study we aimed at assessing whether
ARF carries an increased risk of complications and sub-
optimal delivery of nutrients when the enteral route is
the only means of artificial nutrition.
To this end, we prospectively studied 247 consecutive
patients (182 with ARF) with a period of enteral nutrition
as the sole modality of artificial nutrition, for a total of
2525 days of nutritional support.
We evaluated the incidence of gastrointestinal, me-
chanic, and metabolic complications related to enteral
nutrition. Moreover, we assessed the adequacy of nutri-
ent administration in two ways. First, we calculated the
ratio of administered to prescribed volume of the en-
teral formula and investigating the reasons of possible
discrepancies. Second, we compared the actual intake of
calories and proteins with theoretic needs, and investi-
gated whether the differences were due to underdelivery,
999
1000 Fiaccadori et al: Enteral nutrition in acute renal failure
underprescription, or inappropriate enteral formula
composition.
METHODS
Study population
We studied all patients receiving a period of artificial
nutrition during which they were fed only by the enteral
route over a 96-month time span (January 1, 1994, to De-
cember 31, 2002), at the Renal Intensive Care Unit (ICU)
of the Internal Medicine & Nephrology Department, in
a 1300-bed acute care university-based teaching hospital.
We included either patients receiving enteral nutri-
tion before transferral to our unit, or patients who were
started on enteral nutrition at our unit.
The renal ICU is a closed six-bed specialty unit for
ARF patients, with a bed to nurse ratio of 3:1. It is staffed
by nephrologists with advanced experience in critical
care nephrology. Being equipped with facilities for inva-
sive and noninvasive mechanical ventilation since 1999,
the renal ICU serves also as a general ICU for med-
ical/surgical patients (with respiratory, cardiac, hepatic
failure, etc.).
ARF was defined as an abrupt decline in renal function
with a recent rise (24 to 48 hours) in plasma creatinine of
more than 50% above baseline values in the absence of
volume-responsive prerenal status; in the case of preex-
isting renal disease, or known renal insufficiency that had
not yet reached the end stage, patients were required to
demonstrate an increase in serum creatinine levels of at
least 1 mg/dL from their baseline status (acute on chronic
renal failure) [1].
Some of the ARF patients considered in the present
study received renal replacement therapy; others, with
or without ARF, were also receiving mechanical ventila-
tion (invasive or noninvasive). Renal replacement ther-
apy consisted in low-temperature (35◦C), bicarbonate,
intermittent hemodialysis without heparin, or continu-
ous venovenous hemofiltration (CVVH) with prostacy-
clin, or sustained low-efficiency dialysis (SLED) with
prostacyclin. Only high-compatibility filters (polysulfone,
polymethylmethacrylate, poliacrylonitrile, and ethylviny-
lalcohol) were used throughout the study period.
The attending physicians established the indications
for artificial nutrition, namely when to start, whether to
administer it via the parenteral or enteral route, as well
as the amount of nutritional supply. The indications for
artificial nutrition were based on the available ASPEN
Guidelines [4, 12]. The choice of the feeding route was
up to the attending physician. Usually enteral nutrition
was not started if the patient suffered from malabsorption
with severe nutrient loss, electrolyte and fluid losses not
adequately managed orally or by enteral nutrition, gas-
trointestinal motility disorders (such as persistent post-
operative disease or drug-related ileus, severe vomiting,
etc.), mechanical intestinal obstruction not immediately
relieved by surgical intervention, necrotic-hemorrhagic
pancreatitis, high nasogastric drainage, etc.
Parenteral nutrition was used to maintain nutrient re-
quirements in these cases, as well as when enteral nutri-
tion had to be withdrawn because of complications.
Enteral feeding and its monitoring
All patients were fed by 10 to 12 Fr polyurethane naso-
gastric tubes (Abbott, Latina, Italy) placed in the stom-
ach by the ICU physicians or nurses. Tube placement was
verified before diet administration by insufflating 50 to
100 mL of air down the tube during epigastric ausculta-
tion and/or by abdomen plain x-ray films, if needed. All
patients were fed in a semirecumbent position, with the
head elevated to 45◦. Feeding was always infused at a con-
stant rate over 24 hours by a pump, and the containers
and delivery systems were changed every 24 hours of use.
Nasogastric tubes were flushed with at least 50 mL
of water every 8 hours; gastric residual volumes were
checked before flushing. Every 8 hours oral/nose care was
carried out; patients on invasive mechanical ventilation
had cuff pressure checked at the same time intervals.
Enteral feeding was not routinely stopped for routine
bedside medical procedures, renal replacement thera-
pies, or usual nursing care procedures (i.e., patient baths,
dressing changes, changing bed linens, management of
tracheostomy tubes), unless specifically ordered by the
physician. In the case of accidental removal or definitive
obstruction of nasogastric tube, enteral nutrition protocol
allowed a maximal time of 30 minutes before undertaking
its repositioning.
We used either standard polymeric diets (Osmolite;
(Abbott), 840 nonprotein kcal/L, 40 g proteins/L, with
or without glucose polymers addition (Polycose; Abbott)
2 kcal/mL, or disease-specific diets: Dialycare (Abbott),
1720 nonprotein kcal/L, 70 g proteins/L or Renalcare
(Abbott), 1880 nonprotein kcal/L, 30 g proteins/L. Di-
ets were always administered at full strength. In the case
of standard polymeric diet, the initial rate was set at
30 mL/hour and increased by 20 mL/hour/day every 24
hours; in the case of specialized (more concentrated) re-
nal diets, the initial rate was set at 20 mL/hour the first
day and increased by 10 mL/hour/day every 24 hours un-
til achieving the intended goal. Daily caloric intake goals
were at least 20 nonprotein Kcal/kg in patients with nor-
mal renal function, and 25 kcal/kg in patients with ARF;
protein goal was at least 0.8 g/kg in ARF patients not
on renal replacement therapy, and at least 1 g/kg/day in
those on renal replacement therapy. For an average 75 kg
patient, the above goals are usually reached by adminis-
tering about 1700 mL/day of the standard polymeric diet,
or 840 mL/day of the specialized renal diet. In some ARF
patients on renal replacement therapy, a standard 10%
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amino acid solution (up to 500 mL) was infused during
the renal replacement therapy session, at discretion of
the attending physician.
Data collection
Starting from January 1994, a prospective database has
been kept at our unit, both as a quality control tool and
to study prognostic indicators of morbidity and mortality
in ARF [1, 13, 14]. The database includes complete de-
mographic and clinical data, characteristics of potential
prognostic significance, nutritional status, nutritional sup-
port, serial clinical parameters and laboratory data, and
complications. Data were recorded on preprinted forms.
Nutritional status was evaluated on admission, as per unit
routine, by the Subjective Global Assessment of Nutri-
tional Status method [1, 15]. Body weight was recorded
at the time of enteral nutrition start. Moreover, for each
patient, the Acute Physiology and Chronic Health Evalu-
ation score in version II (APACHE II) was also calculated
[16]. Following admission, data concerning treatments,
procedures, and complications during the patient’s stay
were collected daily. Renal replacement therapy required
until death, hospital discharge, or treatment discontinu-
ation was recorded as hemodialysis, CVVH, or sustained
low-efficiency dialysis.
Data concerning nutritional support included pre-
scribed and actually administered daily calories and pro-
teins. Moreover, in the case of patients receiving enteral
nutritition, the following data were also recorded: time
of first feeding; type and caliber of feeding tube; type
of nutrient formula; duration of enteral nutrition; and
enteral nutrition-related complications (gastrointestinal,
mechanical and metabolic).
Patients were monitored for enteral nutrition–related
complications at least twice at each nurse shift, or
even more frequently, if needed. Each complication was
recorded daily. An enteral nutrition–related complica-
tion was defined as an event that required tube feeding
to be temporarily stopped, a reduction in feeding admin-
istration rate, or definitive enteral nutrition withdrawal.
Gastrointestinal and mechanical complications were
defined and managed as described in the Appendix.
As to the metabolic complications, hyperglycemia was
defined as serum glucose values above 180 mg/dL; hypo-
glycemia as serum glucose values lower than 80 mg/dL.
In case of hyperglycemia, intravenous continuous infu-
sion of regular insulin by a volumetric pump was started.
Metabolic complications were collected as prevalence
data (i.e., present either at admission or at any time during
stay, and as the proportion of days in which the compli-
cation persisted).
Parenteral nutrition replaced enteral nutrition in case
the latter had to be interrupted because of complications.
Causes of withdrawal were recorded.
Compliance with the enteral nutrition orders was
measured by comparing the difference between daily
prescribed and actually administered volumes of enteral
nutrition formulas. We calculated the ratio of adminis-
tered to prescribed volume as the index of efficacy of
daily nutrient delivery by enteral nutrition. Appropriate
delivery was defined if more than 90% of prescribed vol-
umes was administered.
Patients were followed until they tolerated enteral nu-
trition, were started on oral nutrition, were discharged
from the unit, or died. As the study was observational,
data had to be collected anyway for quality control and
clinical use, and the institutional feeding protocol had not
to be modified for study purpose, we sought neither the
approval from the local Ethics Committee, nor the writ-
ten consent from the patients.
Missing values
Baseline characteristics were available for all patients
except for APACHE II score, which was missing in
29 patients. Body weight was missing in one patient.
Some data collected daily were also missing. Three
patients (11 days) were missing in the group with nor-
mal renal function, four patients (6 days) in the group
with ARF not on renal replacement therapy, and three
(11 days) in the group with ARF on renal replacement
therapy. Missing data were mostly due to logistic reasons,
thus they were likely to be random. In fact, clinical char-
acteristics of patients with missing data did not seem to
differ from the others.
Data analysis
To verify whether the presence of acute renal failure
was associated with other clinical variables and whether it
increased the risk of complications we tested for trend the
three groups using regression models in which each group
was given a score which was entered as a continuous inde-
pendent variable. For the trend in continuous dependent
variables these models were ordinary least-square regres-
sions where the dependent variables were transformed,
whenever needed, to improve normality. For the depen-
dent categorical variables, these models were logistic re-
gressions and the P values were computed by likelihood
ratio test.
To examine the amount and pattern of administered
nutrients we used mixed models for repeated data [17].
We excluded from all the computations the first and last
day of enteral nutrition, because admissions and trans-
ferrals to our unit most often occur in the evening, while
discharges and transferrals to other departments most of-
ten occur in the morning. This led to the exclusion of 15
patients who were treated only for 1 or 2 days, and a to-
tal of 481 days of enteral nutrition. Thus, these analyses
concerned 222 patients out of 247 (60 with normal renal
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function, 59 ARF not on renal replacement therapy, and
103 with ARF on renal replacement therapy) followed
for a total of 2016 days. Data were highly unbalanced,
the number of days available for the analyses ranging
from 1 to 51 per patient. We used a random coefficient
model which included cubic splines [17, 18] to examine
the non linear time change of administered calories and
proteins, the difference in the time change between the
three groups, and the difference in the average amount of
nutrients administered. It was adjusted for body weight,
since body weight, a major determinant of underdelivery
of nutrients in our study population, tended to differ in
the three groups.
Either the analyses on the risk of complications and
those of administered nutrients were repeated after ad-
justment for age, gender, diabetes, nonrenal APACHE
II, type of surgery, and mechanical ventilation. We do
not report the results since they were virtually identical
to the unadjusted ones. All analyses described so far were
performed using GenStat software, Release 6.1 (VSN In-
ternational, Oxford, UK).
To verify whether the periods of suboptimal rate of
delivery (i.e., below 90% of the daily prescribed rate)
were associated with enteral nutrition–related complica-
tions, we used LogXact-5 software (2002, Cytel Software
Corporation, Cambridge, MA, USA) to compute exact P
values from conditional logistic regression models, which
included the patients as stratum variable and the compli-
cation as the independent variable.
Fisher’s exact test was used for the nonstratified two-
sample comparisons.
RESULTS
Over the 9-year study period, 1267 patients were hos-
pitalized in the unit; 636 patients received artificial nu-
trition; 247 patients had one period of artificial nutrition
during which they were fed exclusively by the enteral
route, thus only these patients were included in the study.
A total of 2525 days of enteral nutrition were monitored
(Table 1). Table 2 reports the characteristic of the three
study groups. The presence and severity of ARF was
associated with an increase in APACHE II score and
mortality, and to a lower proportion of patients who un-
derwent heart surgery. However, no significant difference
was found in APACHE II values, once the renal part of
the score was not taken into account.
Gastrointestinal and mechanical complications are
summarized in Table 3. The most frequently observed
complications were represented by constipation and di-
arrhea, without any difference between the groups. ARF
patients were instead more likely to have nasogastric tube
obstruction and high gastric residuals. However, aspira-
tion pneumonia was rare in all groups, and it almost exclu-
sively occurred in mechanically ventilated patients. Also,
the incidence of epistaxis was low in all the groups.
Table 1. Patients, enteral nutrition days included, and enteral
nutrition treatment
ARF not ARF
Normal on renal on renal
renal replacement replacement
runction therapy therapy
Patients number (total) 65 68 114
Enteral nutrition days (total) 644 675 1206
Days per patient 7 (2–35) 7 (1–44) 8 (1–53)
Already on enteral nutrition 20 (30.7) 13 (19.1) 24 (21.0)
Body weight 69.2 (15.0) 65.4 (12.7) 68.1 (11.2)
Enteral nutrition formula
Standard polymeric 53 (81.5) 32 (47.1) 20 (17.5)
Standard polymeric 0 (0.0) 11 (16.2) 11 (9.6)
+ glucose polymers
Disease-specific 12 (18.5) 25 (36.7) 83 (73.9)
ARF is acute renal failure. Categorical variables are presented as number (per-
centage); continuous variables as mean (standard deviation) or median (range).
Observed metabolic disorders are illustrated in Table 4.
No difference between groups was found regarding dis-
orders of glucose and sodium, while, as expected, hyper-
kaliemia, hyperphosphatemia, hypermagnesemia, and
hypocalcemia were more frequently observed in ARF
patients, especially those on renal replacement therapy.
No patient required enteral nutrition withdrawal for
metabolic complications.
Not shown in these tables is the relationship between
these complications and the type of enteral nutrition for-
mula used. The incidence of tube obstruction associated
with the use of disease-specific formulas was higher than
with standard polymeric formulas (10% vs. 1%, P =
0.003). In contrast, we found no difference in the inci-
dence of diarrhea (15.0 vs. 22.9%, P = 0.17), and in other
mechanical complications, such as abdominal distention
and high gastric residual (data not shown). As to the
metabolic complications, the prevalence of hypocalcemia
was higher with the use of disease-specific formulas (P =
0.003); there was also a trend toward a higher prevalence
of hyperkalemia (P = 0.053). However, the association
with electrolyte disorders was likely due to the preferen-
tial use of disease-specific formulas in patients with the
most severe derangement of renal function.
The extent of underdelivery of nutrient volume (i.e.,
prescribed vs. administered) is illustrated in Figure 1.
Although administered volumes were significantly lower
than prescribed volumes (P < 0.001), the ratio of admin-
istered to prescribed volumes was around 98% in all three
groups. Reduced administered volume occurred via tem-
porarily interruptions of enteral nutrition (20.7% of the
patients and 12.2% of the days of treatment), or reduced
administration rate (13.6% of the patients and 12.9% of
the days of treatment); it led to suboptimal delivery (i.e.,
below 90% of the daily prescribed rate) for at least one
day in 68/222 (30.6%) of the patients.
Complications of enteral nutrition were a determinant
of suboptimal delivery. Out of the 222 patients whose rate
of delivery was followed daily, 65 (29.3%) developed at
least one of the following complications: nasogastric tube
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Table 2. Demographic and clinical characteristics of the study population
ARF not on renal ARF on renal
Normal renal replacement replacement
function (N = 65) therapy (N = 68) therapy (N = 114) P for trend
Age years 66.9 (13.1) 70.9 (11.5) 71.1 (12.5) 0.014
Male gender 39 (60.0) 42 (61.8) 81 (71.0) 0.11
APACHE II score 14.6 (7.9) 21.1 (6.8) 24.0 (7.5) <0.001
Mortality
In-hospital 12 (18.5) 16 (23.5) 42 (36.8) 0.006
Intensive care unit 8 (12.3) 13 (19.1) 34 (29.8) 0.004
Nonrenal APACHE II 14.6 (7.9) 14.5 (6.8) 16.6 (7.4) 0.11
Surgical 35 (53.8) 32 (47.1) 31 (27.2) <0.001
Cardiac or major vascular surgery 25 (38.5) 20 (29.4) 18 (15.8) <0.001
Abdominal surgery 7 (10.8) 9 (13.2) 11 (9.6) 0.74
Creatinine mg/dL 0.9 (0.4–1.3) 3.0 (1.9–9.4) 6.1 (2.0–19.5) <0.001
Blood urea nitrogen mg/dL 21 (7–45) 67 (24–119) 92 (48–256) <0.001
Renal replacement therapy
Hemodialysis — — 83 (73)
CVVH — — 17 (15)
SLED — — 14 (12)
SIRS 30 (46.1) 31 (45.6) 60 (52.3) 0.36
Sepsis
At admission 18 (27.7) 16 (23.5) 29 (25.4) 0.79
Complication 18 (27.6) 17 (25.0) 42 (36.8) 0.15
Mechanical ventilation 23 (35.4) 27 (39.7) 47 (41.2) 0.45
Diabetes mellitus 17 (26.1) 14 (20.6) 22 (19.3) 0.30
Severe malnutrition (SGA Class C) 26 (40.0) 25 (36.8) 54 (47.4) 0.26
Abbreviations are: ARF, acute renal failure; CVVH, continuous venovenous hemofiltration; SLED, sustained low-efficiency dialysis; SGA, subjective global assessment
of nutritional status; SIRS, systemic inflammatory response syndrome; APACHE II, Acute Physiology and Chronic Health Evaluation score in version II; nonrenal
APACHE II, the APACHE II score with the renal score subtracted. Categorical variables are presented as number (percentage); continuous variables as mean (standard
deviations) or median (range).
obstruction, tube removal, epistaxis, high gastric residual,
abdominal distention, and diarrhea. Of these 65 patients,
58 (89.2%) received suboptimal rate of infusion for at
least 1 day, whereas this occurred in only 10 (6.4%) of
the 157 patients not developing these complications (P <
0.001). Table 5 shows this phenomenon in more details,
and in each group separately. At variance with diarrhea,
which was significantly associated with suboptimal rate
of infusion in every group, high gastric residual, tube ob-
struction and tube removal were associated with subop-
timal rate of infusion mainly in patients suffering from
ARF.
Mean delivered nonprotein calories at regimen were
19.8 kcal/kg (SD 4.6), 22.6 kcal/kg (8.4), and 23.4 kcal/kg
(6.5) in patients with normal renal function, in patients
with ARF not on renal replacement therapy, and in pa-
tients with ARF on renal replacement therapy, respec-
tively; their protein intake 0.92 g/kg (SD 0.21), 0.87 g/kg
(0.25), and 0.92 g/kg (0.21); their median fluid intake with
enteral nutrition 1440 mL (range 720 to 1960), 1200 mL
(720 to 2400), and 960 mL (360 to 1920).
As depicted in Figure 2, the time course of daily ad-
ministered nonprotein calories and proteins was similar
in the three groups (P = 0.84 and P = 0.31, respectively).
The full regimen was reached on average by the fourth
day since start in all the groups. There was a statistical
difference in the absolute amount of nonprotein calories
administered (P < 0.001) due to lower prescription in pa-
tients with normal renal function. In contrast, the amount
Table 3. Mechanical and gastrointestinal complications of enteral
nutrition
ARF not ARF on
Normal on renal renal
renal replacement replacement
function therapy therapy P for
(N = 65) (N = 68) (N = 114) trend
Mechanical
Tube obstruction 0 (0.0) 4 (5.9) 16 (14) <0.001
Pain in the pharynx 1 (1.5) 3 (4.4) 3 (2.6) 0.92
Epistaxis 0 (0.0) 3 (4.4) 3 (2.6) 0.37
Aspiration pneumonia 1 (1.6) 1 (1.5)a 3 (2.6)b 0.58
Gastrointestinal
High gastric residual 2 (3.1) 5 (7.4) 15 (13.2) 0.02
Vomiting 3 (4.6) 6 (8.8) 8 (7) 0.62
Abdominal distention 2 (3.1) 0 (0.0) 2 (1.7) 0.63
Constipation 12 (18.5) 12 (17.6) 21 (18.4) 0.99
Diarrhea 12 (18.5)c 12 (17.6) 18 (15.8)d 0.63
Prokinetic drug usee 10 (15.4) 6 (8.8) 20 (17.4) 0.53
ARF is acute renal failure. Data are reported as number (percentage) of
patients.
aOne/one on mechanical ventilation; bthree/three on mechanical ventilation;
cTwo positive for Staphylococcus aureus; dOne positive for S. aureus; ecisapride,
metoclopramide. There was no difference in the use of either prokinetic drug
between the groups (data not shown).
of proteins administered by the enteral route was similar
in the three groups (P = 0.61); enteral nutrition was sup-
plemented with parenteral amino acids in 40/114 patients
on renal replacement therapy (35.1%), who received
500 mL of a 10% amino acid solution during treatment.
We found that body weight was a major determinant
of underprescription irrespective of the presence of ARF.
Table 6 show intakes after stratification of the patients in
those with body weight above 70 kg (39% of the total,
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Table 4. Metabolic complications
ARF not on renal ARF on renal
Normal renal replacement replacement
function (N = 65) therapy (N = 68) therapy (N = 114) P for trend
Glucose homeostasis
Hyperglycemia (glucose >180 mg%) 13 (20.0) 17 (25.0) 35 (30.7) 0.11
Enteral nutrition days with hyperglycemia 10.9 11.3 13.6 0.17
Hypoglycemia (glucose < 80 mg%) 3 (4.6) 5 (7.3) 9 (7.9) 0.42
Enteral nutrition days of hypoglycemia 0.6 2.2 1.1 0.42
Use of insulin 18 (27.7) 26 (23.5) 27 (23.7) 0.58
Maximum insulin dose (IU/24 hours) 50 (24–96) 42 (10–96) 48 (10–144) 0.34
Electrolytes
Hypernatremia (Na > 145 mEq/L) 11 (16.9) 20 (29.4) 15 (13.2) 0.30
Enteral nutrition days with hypernatremia 3.1 12.4 2.5 0.25
Hyponatremia (Na < 135 mEq/L) 8 (12.1) 6 (8.8) 13 (12.4) 0.93
Enteral nutrition days with hyponatremia 4.6 3.8 2.1 0.83
Hyperkalemia (K > 5.3 mEq/L) 3 (4.6) 10 (14.7) 45 (39.5) 0.001
Enteral nutrition days with hyperkalemia 0.5 3.4 11.9 <0.001
Hypokalemia (K < 3.5 mEq/L) 6 (9.2) 18 (26.5) 16 (14.0) 0.67
Enteral nutrition days with hypokalemia 1.2 8.8 3.7 0.63
Hyperphosphatemia (P > 5.5 mg/dL) 4 (6.1) 17 (25) 54 (47.4) <0.001
Enteral nutrition days with hyperphosphatemia 1.6 7.4 13.7 <0.001
Hypophosphatemia (P < 3.0 mg/dL) 11 (16.9) 14 (20.6) 29 (25.4) 0.18
Enteral nutrition days with hypophosphatemia 3.3 3.2 4.9 0.13
Hypercalcemia (Ca > 10.5 mg/dL) 2 (3.1) 1 (1.5) 5 (4.4) 0.54
Enteral nutrition days with hypercalcemia 0.4 0.1 1.5 0.65
Hypocalcemia (Ca < 8.5 mg/dL) 12 (18.5) 34 (50) 76 (66.7) 0.001
Enteral nutrition days with hypocalcemia 10.0 30.7 37.3 0.001
Hypermagnesemia (Mg >2.5 mg/dL) 0 (0.0) 14 (20.6) 20 (17.5) 0.003
Enteral nutrition days with hypermagnesemia 0.0 4.0 3.6 0.03
Hypomagnesemia (Mg < 1.2 mg/dL) 1 (1.5) 3 (4.4) 5 (4.4) 0.36
Enteral nutrition days with hypomagnesemia 0.5 0.7 0.9 0.37
ARF is acute renal failure. Data are reported as number (percentage) of patients, and proportion of days with the complication. Maximum dose of insulin is reported
as median (range).
average weight 80.5 kg), and those below 70 kg (61%
of the total, average weight 59.8 kg). High body weight
was a major determinant of underprescription of nutri-
ent intakes (P < 0.001 for either nonprotein calories and
proteins) in all the groups.
Finally, Table 7 shows causes of definitive enteral nu-
trition withdrawal. The majority of patients had enteral
nutrition withdrawn due to clinical reasons rather than
to enteral nutrition poor tolerability. There was a trend,
albeit not statistically significant (P = 0.09), for gastroin-
testinal complications to be a more likely cause of enteral
nutrition withdrawal in ARF patients than in patients
with normal renal function.
DISCUSSION
This is the first study that has systematically investi-
gated both the safety and efficacy of artificial nutrition
administered solely via the enteral route in patients with
ARF.
Our results suggest that also in this clinical setting, en-
teral nutrition practice can be implemented without in-
curring in undue complications. Moreover, provided that
nursing personnel strictly adhere to enteral feeding pro-
tocols, enteral nutrition allows the delivery of adequate
caloric intake, while keeping fluids restrained. However,
in ARF patients on renal replacement therapy, parenteral
Normal renal function
ARF not on RRT
ARF  on RRT
Prescribed
Administered
0 500 1000 1500
Volume of enteral formula, mL
Fig. 1. Mean prescribed ( ) and administered ( ) volumes in the three
groups. Administered vs. prescribed volumes P < 0.001 in all groups.
Abbreviations are: ARF, acute renal failure; RRT, renal replacement
therapy.
amino acid supplementation may be required to achieve
currently recommended protein intakes.
Two potential limitations of our study must be acknowl-
edged. The first concerns the possibility of generalizing
our findings; the second regards the validity of the com-
parison between the three groups examined.
As to the first issue, all the patients were hospitalized at
the same institution, thus the results might not hold true
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Table 5. Relation between complications and enteral nutrition delivery
Normal ARF not on renal ARF on renal
renal function replacement therapy replacement therapy
Delivered to prescribed enteral
nutrition volume ratio <90% ≥90% <90% ≥90% <90% ≥90%
Enteral nutrition days 29 481 22 511 73 900
Tube obstruction 0 (0.0) 0 (0.0)a 1 (4.5) 4 (0.80)a 14 (19.2) 7 (0.8)b
Tube removal 1 (3.4) 1 (0.2)a 0 (0.0) 0 (0.0)a 12 (16.4) 1 (0.1)c
Epistaxis 1 (0.8) 1 (0.1)a 1 (4.5) 1 (0.2)a 0 (0.0) 0 (0.0)a
High gastric residual 2 (6.9) 2 (0.4)a 2 (9.1) 0 (0.0)c 16 (21.9) 1 (0.1)b
Vomiting 4 (13.8) 2 (0.4)d 1 (4.5) 0 (0.0)a 2 (2.7) 1 (0.1)a
Abdominal distention 1 (3.4) 0 (0.0)a 0 (0.0) 0 (0.0)a 0 (0.0) 0 (0.0)a
Diarrhea 10 (34.5) 1 (0.2)b 9 (40.9) 2 (0.4)b 15 (20.5) 2 (0.2)b
Diagnostic or surgical procedures 2 (6.9) 0 (0.0)d 1 (4.5) 0 (0.0)a 3 (4.1) 3 (0.3)d
Not defined 1 (3.4) 0 (0.0)a 1 (4.5) 1 (0.2)a 1 (1.4) 2 (0.2)a
ARF is acute renal failure. Data are reported as number (proportion) of days with the complication.
Symbols refer to statistical tests comparing, in each group, the frequency of complications occurring during periods of suboptimal delivery (<90% of the prescribed
amount) with that occurring during periods of optimal delivery (≥90% of the prescribed amount): aP ≥ 0.05; bP < 0.001; cP < 0.01; dP < 0.05.
in other clinical settings. However, the clinical practice at
our unit resembles that of most centers involved in enteral
nutrition; and ARF patients we have studied embrace the
entire spectrum of severity of the syndrome. A further
potential problem lies in the fact that the present study
may have included a selection of patients in whom enteral
nutrition was more likely to be tolerated. However, since
the decision to administer enteral nutrition rather than
parenteral nutrition was based on the preferences of the
attending physician, which are somewhat unrelated to
the type of patient being treated, our study population is
meant to be a representative sample of all patients who
are candidates for artificial nutrition (with the obvious
exception of those with clear contraindications to enteral
nutrition).
As to the validity of the comparison between groups,
the differences between them may not be limited to the
presence of ARF with renal replacement therapy require-
ments, but may also concern clinical characteristics re-
lated to enteral nutrition tolerability. However, we did
not find major differences in clinical characteristics be-
tween these three groups. In particular, they were similar
with respect to non-renal comorbidities (i.e., non-renal
APACHE II score, mechanical ventilation, diabetes, and
sepsis). The only major difference was the higher pro-
portion of patients who underwent heart surgery in the
group with normal renal function. Yet, in our opinion,
this characteristic has little association with the tolerabil-
ity of enteral nutrition. As confirmation of our opinion,
when we adjusted the analyses for these characteristics,
the results were similar.
Contrary to our expectations, we did not find an in-
creased incidence of major gastrointestinal complications
such as vomiting, diarrhea, constipation, and abdominal
distention in patients with ARF. Only the incidence of
high gastric residual volumes appeared to be higher in
these subjects. However, an increased incidence of aspi-
ration pneumonia, or reduced delivery of nutrients did
not accompany this phenomenon, and even despite the
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Fig. 2. Mean of nonprotein (NP) calories and of proteins administered
daily in the three groups over the first 3 weeks from start of enteral nu-
trition. Means are adjusted for body weight. No difference in the time
course of nutrient administration was observed. The only statistical dif-
ference regarded the absolute amount of nonprotein calories, which was
lower in patients with normal renal function (P < 0.001). Abbreviations
are: ARF, acute renal failure; RRT, renal replacement therapy.
Table 6. Nutrient amounts according to body weight
ARF not ARF on
Normal on renal renal
renal replacement replacement
function therapy therapy
Nonprotein kcala kcal/kg
Body weight < 70 kg 21.6 (4.3) 25.2 (8.6) 25.8 (8.0)
Body weight ≥ 70 kg 16.8b (3.4) 17.9b (5.5) 19.9b (5.4)
Proteinsa g/kg
Body weight < 70 kg 1.00 (0.18) 0.95 (0.25) 0.99 (0.19)
Body weight ≥ 70 kg 0.77b (0.16) 0.74b (0.21) 0.82b (0.20)
ARF is acute renal failure. Data are reported as mean (standard deviation).
aAt full regimen; bP < 0.001, comparing patients with body weight < 70 kg.
well-known hemorrhagic risk of ARF patients, the fre-
quency of epistaxis was similar in the three groups. On
the other hand, ARF patients had a higher incidence of
tube obstruction, due to the use of more concentrated
disease-specific formulas.
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Table 7. Reasons for definitive withdrawal of enteral nutrition
ARF not ARF on
Normal on renal renal
renal replacement replacement
Rasons for function therapy therapy
withdrawal (N = 65) (N = 68) (N = 114)
Clinical 61 (93.8) 59 (86.8) 97 (85.1)
Shift to oral feeding 30 (46.1) 38 (55.9) 51 (44.7)
Transferral to other wards 21 (32.3) 9 (13.2) 10 (8.8)
Artificial nutrition refusal 0 (0.0) 1 (1.5) 6 (5.2)
Surgery 1 (1.5) 1 (1.5) 5 (4.4)
Death or terminal illness 9 (13.8) 10 (14.7) 25 (21.9)
Enteral nutrition–related 4 (6.1) 9 (13.2) 17 (14.9)
complicationsa
Diarrhea 3 (4.5)b 4 (6.1)c 8 (7.0)b
Epistaxis 0 (0.0) 0 (0.0) 1 (0.9)
Nasogastric tube obstruction 0 (0.0) 2 (2.9) 1 (0.9)
High gastric residual 0 (0.0) 2 (2.9) 4 (3.5)
and/or vomiting
Aspiration pneumonia 1 (1.5) 1 (1.5) 3 (2.6)
ARF is acute renal failure. Data are reported as number (percentage) of pa-
tients.
aTrend across the three groups, P = 0.09; bTwo positive for Clostridium difficile
toxin assay; cOne positive for C. difficile toxin assay.
Gastrointestinal problems are the most frequent en-
teral nutrition–related complications in critically ill
patients, as well as the main cause of suboptimal nutri-
ent delivery via the enteral route [17–22]. The most com-
monly observed gastrointestinal complications are high
gastric residual volume and diarrhea, which on the whole
can occur in 15% to over 50% of the patients [21–25].
Multiple factors negatively affect gastrointestinal empty-
ing in critically ill patients, such as medications (sedatives,
opiates, catecholamines, etc.), glucose and electrolyte dis-
orders, diabetes or mechanical ventilation [20, 25]. In pa-
tients with ARF, the gastroparesis often bound to the
uremic syndrome could further worsen the situation, as
is documented in chronic hemodialysis patients [26]. In
this respect, however, a few circumstances must be con-
sidered. First, even though the threshold for defining gas-
tric residual volume as “high” was in our study similar or
even below the commonly utilized values [20, 25], the
absolute incidence of this complication in ARF patients
was lower than previously reported in critically ill patients
[19, 20, 25]. Second, and most important, in ARF patients,
high gastric residual volume was a very infrequent cause
of definitive withdrawal of enteral nutrition. Third, al-
though it is well known that aspiration of gastric content
is a possible mechanism of pneumonia in the critically
ill, this complication was very uncommon in our series.
It was observed in 1.5% to 2.6% of cases, and almost ex-
clusively in mechanically ventilated patients, regardless
of the degree of impairment in renal function. On this
regard, we cannot exclude that preventive strategies rou-
tinely implemented in our patients (elevating the head
of the patient at 45◦, checking gastric residuals, holding
the feeding in the case of high residuals, and delivering
feeding continuously), could have contributed to the low
complication rate found in our study.
As expected, during the study period the prevalence
of electrolyte derangements at any time during stay was
higher in patients with ARF than in those with normal re-
nal functions, and highest among ARF patients on renal
replacement therapy. We found an increased preva-
lence of hyperkaliemia, hyperphosphatemia, hypermag-
nesemia, and hypocalcemia, whereas glucose and sodium
level derangement rates were not different. These results
must be interpreted with caution since it is well known
that the frequency of electrolyte disorders in ARF pa-
tients can be high, whether or not they receive artificial
nutrition. In spite of that, the frequency of electrolyte
disorders in our ARF patients was similar, or even lower,
than that reported in previous studies on patients with
normal renal function [23, 27]. Most important, no pa-
tient required enteral nutrition withdrawal for these
complications.
In general, the prevalence of hyper- and hypoglycemia
in our population was similar or lower than that previ-
ously reported in patients on enteral nutrition [23, 27].
Remarkably enough, in those studies, a higher threshold
than ours was adopted in order to define hyperglycemia,
namely serum glucose levels higher than 200 mg/dL [23]
or even 250 mg/dL [27]. It is also noteworthy that in our
study glycemic complications were no more frequent in
ARF patients than in subjects with normal renal func-
tion, while it is known that an acute decline in renal func-
tion can be associated with glucose tolerance impairment
[2]. However, it is to be stressed that recently, a more
strict glycemic control strategy (levels maintained at 80 to
110 mg/dL) has been recommended for critically ill pa-
tients on artificial nutrition, as it is associated with re-
duced mortality and morbidity [28].
To sum up our results on the safety of enteral nutrition
in ARF, we found no evidence that this syndrome cause
a serious increase of either gastrointestinal, mechanical,
or metabolic complications.
In a number of studies, it has been pointed out that
enteral nutrition as the sole nutritional support modality
may not provide adequate amounts of nutrients to hos-
pitalized patients [21, 29–32]. This is a drawback possibly
due to (1) underdelivery of nutrients (i.e., discrepancies
between prescribed and actually delivered amounts of
enteral nutrition formulas exist). This is usually due to
gastrointestinal problems, or other causes, such as slow
progression of administration rates after enteral nutrition
start, or frequent interruptions and delayed re-starting;
and (2) underprescription of nutrients (i.e., calculated pa-
tients’ needs are underestimated by the attending physi-
cians [20, 28–30]).
In the present investigation we found that underdeliv-
ery of enteral nutrition formulas was a minor problem in
all of the three study groups, whereas underprescription
occurred in some instances, notably in both patients with
ARF on renal replacement therapy (in whom protein
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supply was lower than usually recommended intake), and
high weight patients, whose protein and calories intake
was low, regardless of renal function.
As to underdelivery, the ratio of administered to pre-
scribed enteral formula was well over 90% in all groups, at
variance with previous reports on ICU patients, in which
the ratio values ranged from 50% to 85% [21, 29–32]. Var-
ious reasons might explain the higher compliance with en-
teral nutrition prescriptions of this study. First, in our unit
we have implemented a standardized enteral nutrition
protocol, which does not allow cessation of tube feeding
in the course of usual nursing care activities; moreover,
in the case of a dislodged tube, or return of the patients
from diagnostic or surgical procedures, enteral nutrition
was required to be resumed within 30 minutes. In this re-
gard, our results confirm previous observations stressing
the importance of enteral nutrition administration pro-
tocols in order to obtain high ratios of administered to
delivered enteral nutrition volumes [22]. Second, as for
ARF patients, the use of more concentrated formulas, and
thus lower volumes, may have also contributed to the bet-
ter compliance with enteral nutrition orders. Third, the
proportion of patients who underwent major abdominal
surgery was lower in our series in comparison with some
other studies on enteral nutrition.
An important finding of our study was that in ARF
patients the prescription of nutrients to be delivered by
the enteral route can be suboptimal.
Prescription of optimal energy and protein intake is of-
ten inadequate in critically ill patients. In fact, values for
prescribed to calculated nutrient intake ratios as low as
58% to 78% of required needs are reported in the litera-
ture [21, 22, 29–32]. Moreover, even in case of parenteral
supplementation of patients already on enteral nutrition,
only 80% of the caloric requirements were actually pre-
scribed [31].
Improvement of nitrogen balance has been docu-
mented in 14 moderately catabolic patients with ARF
receiving 1.2 g/kg of proteins and 30 nonprotein kcal/kg
by the enteral route [abstract; Fiaccadori E et al, J Am
Soc Nephrol 7:A0634, 1996) (a subset of patients of the
present study), and in a group of highly catabolic ARF
patients on artificial nutrition with 1.5 g/kg of proteins
and 25 to 30 kcal/kg of nonprotein calories [33]. In our
practice, the non-protein caloric goal was 20 kcal/kg/day
for patients with normal renal function, and at least 25
Kcal/kg/day for ARF patients, with a protein intake goal
of at least 0.8 g/kg/day in ARF patients not on renal re-
placement therapy, and at least 1 g/kg/day in the other
cases. Although on average we kept close to the caloric
goals, we failed to supply an adequate amount of proteins
by using only the enteral route, especially in ARF patients
requiring renal replacement therapy. This was mainly due
to the unbalanced enteral nutrition formulas used, which
had a nonprotein calories to nitrogen ratio higher than
that currently recommended in critically ill patients (i.e.,
above 150, instead of 100 to 120). However, this problem
can in practice be easily overcome by administering par-
enteral amino acids during the daily renal replacement
therapy session, as now routinely done at our institution.
CONCLUSION
Enteral nutrition is a safe method to deliver artificial
nutrition in ARF patients. In this clinical setting, enteral
nutrition allows the delivery of adequate amounts of calo-
ries while restraining the fluid intake; parenteral amino
acid supplementation is, however, recommended in the
case of ARF patients on renal replacement therapy, in
order to achieve currently recommended protein goals.
We suggest that education of healthcare professionals
is fundamental to maximize the delivery of nutrients by
enteral nutrition in ARF patients, a population at high
risk of malnutrition. Even though a combination of en-
teral and parenteral nutrition is sometimes needed to
achieve the optimal nutritional support in this clinical
setting, as more generally in the critically ill [34], enteral
nutrition must take on a central role in the complex ther-
apeutic strategy of ARF patients. As a matter of fact, it is
well acknowledged that the advantages of enteral nutri-
tion go well beyond those deriving from the simple supply
of nitrogen and energy at a more favourable cost [35].
APPENDIX
Gastrointestinal complications
Abdominal distention: Increased abdominal volume at physical ex-
amination, with or without bowel sounds. Enteral formula adminis-
tration was stopped until any intra-abdominal pathologic process was
ruled out. If bowel sounds were present despite abdominal distention,
the infusion rate was halved and the patient was re-evaluated 12 hours
later; if the distention had disappeared, the previous infusion rate was
resumed, otherwise enteral nutrition was definitively withdrawn.
High gastric residual: Gastric residual volume twofold than the rate
of diet administration, and/or 150 mL on a single check. Diet infusion
was discontinued for at least 3 hours, and prokinetic agents (cisapride or
metoclopramide) were allowed. If high gastric residual volume persisted
after a second check, enteral nutrition was definitively withdrawn.
Vomiting: Ejection of diet formula from the mouth. In this case, en-
teral nutrition was temporarily stopped, the abdomen was examined for
pathologic changes, the tube position was checked, and enteral feeding
resumed only after correction of detected alterations.
Regurgitation: Enteral formula found in oral or nasal cavities, with or
without exteriorization. Enteral nutrition was not definitively stopped,
and the patients were monitored for possible aspiration and/or aspira-
tion pneumonia.
Diarrhea: Three or more liquid stools over a 24-hour period. Treat-
ment consisted in reducing the administration rate and/or changing the
fluid formula. The use of antidiarrheal medications was not encour-
aged. Stool cultures and samples for Clostridium difficile toxin assay
were obtained routinely.
Constipation: Three or more consecutive days without stools, with
need for treatment with laxatives or enemas according to the attending
physician’s indications. Enemas and laxatives were used without diet
infusion changes.
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Mechanical complications
Obstruction or dislocation or removal (accidental or by the patient)
of nasogastric tube; epystaxis due to nasogastric tube decubitus; and
aspiration, with or without pneumonia. Aspiration was defined as the
presence of enteral nutrition diet detected in the aspirate from the endo-
tracheal tube or during bronchoscopy, and/or a glucose-positive tracheal
aspirate. In case of aspiration enteral nutrition was interrupted. For the
diagnosis of aspiration pneumonia, a new lung infiltrate at diagnosis in
dependent regions was required, as well as at least one of the following
criteria: purulent tracheal or bronchoscopic aspirate, body temperature
>38◦C or <36.5◦C, or white blood cell count of >10000 mm3 or <4000
mm3.
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